Release date- 07082019 -
EyePoint Pharmaceuticals, Inc.
*
Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open)
EyePoint Pharmaceuticals announced the presentation of data supporting the company's Yutiq 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye.
We have decided to focus on our collaboration with Re-Vana Therapeutics concerning biodegradable extended release technologies and have discontinued the collaboration with
Eyepoint Pharmaceuticals (previously pSivida) in this area.
The acquisition accelerates the transformation of pSivida into
EyePoint Pharmaceuticals, a specialty biopharmaceutical company with the potential to launch two ophthalmic products in the first half of 2019 with the FDA approval of DEXYCU, and active regulatory review of Durasert micro-insert for posterior segment non-infectious uveitis.
This makes it easy for eyeglass wearers to see the entirety of the frame, but does make the viewfinder appear just a bit smaller than an identical one with a shorter
eyepoint.
To provide accurate, custom-fit lenses the eyewear designer/retailer uses patented
EyePoint Technology for lens analysis, Edward Beiner offers great style, too!
(1995) Spatial performance with perspective displays as a function of computer graphics
eyepoint elevation and geometric field of view.
EyePoint: Practical pointing and selection using gaze and keyboard.
Spatial discrimination in three-dimensional displays as a function of computer graphics
eyepoint elevation and stereoscopic viewing.